Elorac receives US patent for acne therapy.
M2 EQUITYBITES-February 7, 2014-Elorac receives US patent for acne therapy
(C)2014 M2 COMMUNICATIONS http://www.m2.com
Elorac, a specialty pharmaceutical company focused on the treatment of dermatological disorders, has received US patent No. 8,604,047, entitled 'Method and Composition for Treating Nodulocystic and Conglobate Acne Vulgaris' from the US Patent and Trademark Office, it was reported yesterday.
The patent offers once-weekly oral administration of selective inhibitors of type 1 and/or type 2 isoforms of steroid 5a-reductase, to patients with nodulocystic and conglobate acne vulgaris.
Elorac president and CEO, Dr Jeffrey Bernstein, said, 'We believe our product has many advantages over existing therapies for nodulocystic or conglobate acne.'
((Comments on this story may be sent to email@example.com))